期刊文献+

卡介苗与羟基喜树碱在TURBT术后灌注治疗的疗效对比观察 被引量:1

Comparative Observation on Curative Effect of BCG and HCPT Instillation after TURBT Treatment
下载PDF
导出
摘要 目的评价卡介苗与羟基喜树碱在TURBT术后灌注治疗的对比疗效。方法回顾性分析2009年2月~2013年7月卡介苗与羟基喜树碱在TURBT术后灌注治疗的疗效对比观察的临床资料,其中卡介苗组57例,羟基喜树碱组48例,术后病理分型均为尿路上皮癌,比较2组的肿瘤病理分级、术后复发时间、术后复发率及并发症率。术后随访时间6月~48月,平均30月。结果两组肿瘤分期分级、术后复发时间、术后复发率及并发症率无明显差异。结论卡介苗与羟基喜树碱在TURBT术后灌注治疗中疗效无明显差异。 Objective To assess Comparative efficacy of BCG and HCPT instillation after TURBT treatment.Methods Retrospective analysis of the clinical data of observation from February to 2013in 2009 July with HCPT and BCG perfusion after TURBT treatment,the BCG group 57 cases,HCPT group 48 cases,postoperative pathological types wereurothelial carcinoma,tumor pathological grades,2 groups of postoperative recurrence time,postoperative recurrence rate and complication rate.Postoperative fol ow-up time in 6~48 months,average 30 months.Results Two groups of tumor stage and grade,recurrence time,postoperative recurrence rate and complication rate has no obvious dif erence.Conclusion No significant difference of BCG and the ef ect of HCPT in infusion therapy after TURBT'operation.
作者 何贫 冯征云 佘先 HE Pin;FENG Zheng-yun;Shexian(Department of Surgery,Pixian Chinese Medical Hospital,Chengdu 611730,Sichuan,China;Department of Urology,Qianjiang Central Hospital of Chongqing,Chongqing 409000,China)
出处 《医学信息(医学与计算机应用)》 2014年第14期545-546,共2页 Medical Information
关键词 卡介苗 羟基喜树碱 TURBT术后灌注治疗 BCG HCPT Reperfusion therapy after TURBT
  • 相关文献

参考文献5

二级参考文献60

  • 1孙颖浩,杨波.钬激光在泌尿外科中的应用[J].中华泌尿外科杂志,2005,26(1):62-64. 被引量:210
  • 2夏术阶,于胜强.激光技术在泌尿系统肿瘤治疗中的合理应用[J].现代泌尿外科杂志,2007,12(4):211-213. 被引量:14
  • 3Nguyen CT, Stephenson AJ, Kattan MW. Are nomograms needed in the management of bladder cancer?. Urol Oncol, 2010, 28 : 102-107.
  • 4Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch, 2002, 441 : 105-108.
  • 5Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol, 2008, 54 : 303-314.
  • 6Hong SJ, Cho KS, Han M, et al. Nomograms for prediction of disease recurrence in patients with primary Ta, T1 transitional cell carcinoma of the bladder. J Korean Med Sci, 2008, 23: 428-433.
  • 7van der Heijden AG, Witjes JA. Recurrence, progression, and follow-up in non-muscle-invasive bladder cancer. Eur Urol, 2009, 8 (Suppl) : 556-562.
  • 8Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol, 2006, 49 : 465-466, 475-477.
  • 9Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol, 2000, 163 : 73-78.
  • 10Shariat SF, Margulis V, Lotan Y, et al. Nomograms for bladder cancer. Eur Urol, 2008, 54: 41-53.

共引文献70

同被引文献12

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部